C4 Therapeutics Inc Ordinary Shares CCCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.29
- Day Range
- $3.91–4.30
- 52-Week Range
- $1.69–5.17
- Bid/Ask
- $4.06 / $4.14
- Shares Outstanding
- 110.57M
- Market Cap
- $448.90M
- Volume/Avg
- 46,030 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 104
- Website
- https://www.c4therapeutics.com
Valuation
|
Metric
|
CCCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.86 |
Price/Sales | 11.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CCCC
|
|---|---|
Quick Ratio | 8.75 |
Current Ratio | 9.00 |
Interest Coverage | — |
Quick Ratio
CCCC
Profitability
|
Metric
|
CCCC
|
|---|---|
Return on Assets (Normalized) | −22.48% |
Return on Equity (Normalized) | −34.79% |
Return on Invested Capital (Normalized) | −30.55% |
Return on Assets
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|tx<rhm | LOCK|FW?$& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|N&&%W@ | LOCK|fjfj | $70B | |||
| argenx SE ADR
ARGX
| LOCK|YXXd&b# | LOCK|pm | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&>&^^#z | LOCK|qMt?Q | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|h<qj^F | LOCK|xzy | $36B | |||
| Moderna Inc
MRNA
| LOCK|>wP<tg | LOCK|tJ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|MKxLFBcc | LOCK|r?P@d | $25B | |||
| Incyte Corp
INCY
| LOCK|L&B@N$ | LOCK|G> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Lznm#^c | LOCK|rFg | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#x>pBs# | LOCK|@$ | $17B |
United States